Cogent Biosciences, Inc. $COGT Shares Sold by Rock Springs Capital Management LP

Posted by Geri Gentry on Jul 28th, 2026

Rock Springs Capital Management LP decreased its stake in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 26.5% during the 1st quarter, HoldingsChannel reports. The firm owned 624,155 shares of the technology company’s stock after selling 224,875 shares during the period. Cogent Biosciences comprises 1.4% of Rock Springs Capital Management LP’s holdings, making the stock its 22nd largest position. Rock Springs Capital Management LP’s holdings in Cogent Biosciences were worth $24,024,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the stock. CWM LLC grew its stake in Cogent Biosciences by 4.9% during the 4th quarter. CWM LLC now owns 5,858 shares of the technology company’s stock worth $208,000 after buying an additional 276 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its stake in Cogent Biosciences by 16.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,159 shares of the technology company’s stock valued at $77,000 after buying an additional 300 shares during the last quarter. Optimize Financial Inc boosted its holdings in shares of Cogent Biosciences by 1.4% during the fourth quarter. Optimize Financial Inc now owns 33,024 shares of the technology company’s stock valued at $1,173,000 after acquiring an additional 472 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Cogent Biosciences by 35.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the technology company’s stock valued at $66,000 after acquiring an additional 488 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Cogent Biosciences by 2.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 25,014 shares of the technology company’s stock worth $888,000 after acquiring an additional 527 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and issued a $55.00 price objective on shares of Cogent Biosciences in a report on Friday, May 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Wednesday, July 8th. Finally, HC Wainwright lifted their price target on Cogent Biosciences to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Cogent Biosciences currently has an average rating of “Moderate Buy” and an average price target of $45.90.

View Our Latest Report on Cogent Biosciences

Cogent Biosciences Price Performance

Shares of NASDAQ COGT opened at $40.44 on Tuesday. Cogent Biosciences, Inc. has a twelve month low of $10.38 and a twelve month high of $43.73. The company has a market capitalization of $6.91 billion, a price-to-earnings ratio of -18.64 and a beta of 0.34. The firm has a 50-day moving average of $36.04 and a two-hundred day moving average of $36.39. The company has a current ratio of 15.14, a quick ratio of 15.14 and a debt-to-equity ratio of 0.41.

Cogent Biosciences (NASDAQ:COGT – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The technology company reported ($0.53) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.53). As a group, analysts expect that Cogent Biosciences, Inc. will post -2.26 earnings per share for the current fiscal year.

Cogent Biosciences Profile

(Free Report)

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.